ArticleNAR genomics and bioinformatics2026
Comprehensive mapping of identical sequences across human proteins emphasizes the widespread issue of shared epitopes in self-antigens.
Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shared epitopes pose safety and efficacy issues for T-cell immunotherapy. To characterize the extent of this problem, we performed a computational analysis establishing a complete atlas of shared identical sequences across the human and murine proteomes. Unlike bacterial or viral antigens, self-antigens, including tumor-associated antigens (TAAs), frequently contain sequences of sufficient length to generate identical epitopes in other self-proteins. Epitopes from these shared sequences can theoretically reduce target specificity, confound immunomonitoring studies, and contribute to pre-existing immune tolerance toward TAAs. Notably, a subset of TAAs identified in this atlas is free of this drawback, providing a new criterion for antigen prioritization in cancer immunotherapy. To facilitate the detection of shared sequences, a web server has been made available at https://epitopemapper.ircan.org/ and the open-source code at https://github.com/IRCAN/EpitopeMapper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.